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Scope: The nutrition societies of Germany, Austria, and Switzerland are the
joint editors of the “D-A-CH reference values for nutrient intake”, which are
revised regularly.
Methods and Results: By reviewing vitamin-B12-related biomarker studies,
the reference values for vitamin B12 were revised in 2018. For adults, the
estimated intake is based on the adequate serum concentrations of
holotranscobalamin and methylmalonic acid. The estimated values for
children and adolescents are extrapolated from the adult reference value by
considering differences in body mass, an allometric exponent, and growth
factors. For infants below 4 months of age, an estimated value is set based on
the vitamin B12 intake via breast milk. The reference values for pregnant and
lactating women consider the requirements for the fetus and for loss via
breast milk. The estimated values for vitamin B12 intake for infants, children,
and adolescents range from 0.5 to 4.0 µg d−1. For adults, the estimated values
are set at 4.0 µg d−1, and for pregnant and lactating women, they are set at
4.5 and 5.5 µg d−1, respectively.
Conclusion: Based on the data of several vitamin B12 status biomarkers
studies, the reference value for vitamin B12 intake for adults is raised from 3.0
to 4.0 µg d−1.
1. Introduction
The D-A-CH ‘reference values for nutrient intake’[1] are jointly is-
sued by the nutrition societies of Germany, Austria, and Switzer-
land (the abbreviationD-A-CHarises from the initial letters of the
common country identification for the countries Germany [D],
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Austria [A], and Switzerland [CH]). Ref-
erence value is a collective term for rec-
ommended intake (RI) values, estimated
values, and guiding values. An RI value,
according to its definition, meets the
requirement of nearly any person (ap-
proximately 98%) of a defined group of
metabolically healthy people. Estimated
values are given when human require-
ments cannot be determined with desir-
able accuracy. Guiding values are stated
in terms of aids for orientation.[1]
Reference values for nutrient intake
are amounts that are assumed to
 protect nearly all healthy individuals in
a population from deficiency-related
conditions
 ensure optimal physiological and psy-
chological performance, and
 create a certain body reserve.[2]
Since 2012, the D-A-CH nutrition
societies have published revised refer-
ence values for the intake of several
nutrients[3–11] but not yet for vitamin B12. The last update of the
reference values for vitamin B12 given by the D-A-CH nutrition
societies dates to a 2000 report.[12] Since that time, a number of
new scientific data have become available and have investigated
the relationship between vitamin B12 intake and biomarkers of
vitamin B12 status.[13–15] From this background, there is a need
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to review and update the D-A-CH reference values. In 2018, the
revised reference values for vitamin B12 intake were published in
German. This paper provides a summary of this work.
2. Nutritional Physiology of Vitamin B12
VitaminB12 is the collective term for a number of substanceswith
qualitatively equivalent biological effects. These compounds con-
sist of a corrin ring system that is similar to porphyrin with four
reduced pyrrole rings and a central cobalt ion and are therefore
referred to as cobalamins. Characteristically, all cobalamins have
an α-axial ligand at the cobalt ion consisting of a phosphoribosyl-
5,6-dimethylbenzimidazole side chain. The β-axial position can
be occupied by various substituents. Depending on the group
(R), a distinction is made between cyano- (R = CN), aquo-
(R=H2O), hydroxo- (R=OH),methyl- (R=CH3), and adenosyl-
(R = 5’-deoxyadenosyl) cobalamin.[16] Cobalamins are synthe-
sized only by microorganisms, and humans and animals receive
them solely through the food chain.[17] In natural foods, vita-
min B12 is present mainly as hydroxocobalamin and adenosyl-
cobalamin and is found in milk as methylcobalamin.[18] Due to
its stability, cyanocobalamin is used in fortified foods as well as
in pharmaceuticals and dietary supplements. Some pharmaceuti-
cals and dietary supplements also contain hydroxocobalamin and
methylcobalamin.[19,20]
Humans metabolize cyanocobalamin and hydroxocobalamin
into the two physiologically active coenzymes methylcobalamin
and 5’-deoxyadenosylcobalamin:[17,19]
 Methylcobalamin is a coenzyme of cytosolic methionine
synthase (EC 2.1.1.13) that catalyzes the remethylation of
L-homocysteine to L-methionine. This reaction also involves
folate as 5-methyltetrahydrofolate (5-MTHF), which is the
actual methyl donor. Methylcobalamin that is bound to
the methionine synthase is demethylated in this reaction
and then again remethylated through 5-MTHF. Accordingly,
methylcobalamin is not only involved in the regulation of
L-homocysteine and L-methionine but also required to provide
free tetrahydrofolate (THF), which is an important coenzyme
for the transfer of one-carbon units, for example, in purine
and pyrimidine synthesis.[21]
 5’-Deoxyadenosylcobalamin is a coenzyme of the mi-
tochondrial enzyme L-methylmalonyl-CoA mutase (EC
5.4.99.2). This enzyme isomerizes L-methylmalonyl-CoA to
succinyl-CoA, a central intermediate in the degradation of
odd-chain fatty acids and of the amino acids methionine,
threonine, and isoleucine. In a first step, propionyl-CoA is
converted to D-methylmalonyl-CoA in a reaction catalyzed by
the biotin-dependent propionyl-CoA carboxylase (EC 3.4.1.3).
Thereafter, a racemase converts D-methylmalonyl-CoA to
L-methylmalonyl-CoA.[22] Furthermore, D-Methylmalonyl-
CoA, which is a product of valine and thymine degradation,
is also converted after epimerization to succinyl-CoA through
the L-methylmalonyl-CoA mutase reaction.
The largest vitamin B12 pool in the human body is located in
the liver (approximately 50% of the total body pool). At a mean
total body pool of 3 mg,[23] this amount corresponds to a con-
tent of approximately 1.5 mg in the liver, with 61% present as
adenosylcobalamin, 38% as hydroxycobalamin and only 1% as
methylcobalamin.[18] Significant quantities of vitaminB12 are also
found in skeletal muscles (approximately 9%), bone marrow (ap-
proximately 4.5%) and bowel tissue (approximately 4.5%).[18]
In the blood, cobalamins are transported bound to the
β-globulins transcobalamin (TC)I (haptocorrin) or TC II. The
most physiologically important carrier protein is TC II. The com-
plex formed by vitamin B12 and TC II is referred to as holo-TC II
(simplified synonym holo-TC).[24] The half-life of holo-TC is 60 to
90 min[18,25]; 10–30% of the circulating vitamin B12 is bound to
TC II.[24]
3. Criteria to Assess the Vitamin B12 Status
There are different biomarkers for assessing vitamin B12 status.
These biomarkers include the two status parameters vitamin B12
and holo-TC in serum or plasma and the functional parameters
methylmalonic acid (MMA) and homocysteine in serum.[21,26–32]
However, none of these parameters are sufficient on their own to
adequately assess vitamin B12 status.[29] Furthermore, until now,
no generally accepted cut-off values exist for any of the biomark-
ers. Additionally, several groups have published different cut-off
values.[28,33,34]
3.1. Total Circulating Vitamin B12
A serum or plasma concentration of vitamin B12 between
148 pmol L−1 and 221 pmol L−1 indicates marginal supply,[28]
and a concentration of <148 pmol L−1 indicates vitamin B12
deficiency.[26,28,35] A serum concentration of >221 pmol l−1 may
be considered indicative of a sufficient vitamin B12 status in
adults.[28,36] However, a serum concentration of >221 pmol L−1
may not necessarily mean that the vitamin B12 supply is suffi-
cient since symptoms of vitamin B12 deficiency and/or a func-
tional metabolic vitamin B12 deficiency may also be present.[21,31]
Therefore, the total serum vitamin B12 concentration should be
determined in combination with a functional parameter such as
MMA.[29,30,37]
3.2. Circulating Holo-TC
Circulating holo-TC is responsible for supplying the tissues with
vitamin B12.[38] Thus, the serum holo-TC concentration reflects
the supply of metabolically active cobalamins.[32,39] A holo-TC
concentration between 40 and 100 pmol L−1,[36] 40 and 200 pmol
L−1[39] or >37 and <190 pmol L−1[40] is considered as the target
concentration for a sufficient vitamin B12 status in adults. A holo-
TC concentration of >8.4 to <20 pmol L−1 is indicative of a pos-
sible vitamin B12 deficiency and a concentration of <8.4 pmol
L−1 is indicative of a potential vitamin B12 deficiency.[40] For a
more reliable assessment of vitamin B12 supply, holo-TC should
be determined in combination with a functional parameter such
as MMA.[29,30]
3.3. Circulating MMA
Serum MMA concentration is considered as functional
biomarker of vitamin B12 status. In the case of vitamin B12
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deficiency, the serum concentration of MMA increases
due to a reduced vitamin B12-dependent isomerization of
L-methylmalonic acid to succinyl-CoA through the enzyme
L-methylmalonyl-CoA mutase.[29,35,41] A MMA concentration
of <210 [28] or <270 nmol L−1[36] is considered the target con-
centration for a sufficient vitamin B12 supply in adults. MMA
concentrations of >350 to <840 nmol L−1 are indicative of an
insufficient vitamin B12 status, and MMA concentrations of
>840 nmol L−1 are indicative for a vitamin B12 deficiency.[40]
However, an increased MMA serum concentration may also
occur due to impaired renal function. During pregnancy and
at advanced age, MMA also increases independent of the vita-
min B12 intake. Therefore, the specificity of MMA as a biomarker
for vitamin B12 is limited.[29,35] Thus, MMA should only be used
in combination with a status parameter such as holo-TC.[29,30]
3.4. Circulating Homocysteine
The remethylation of homocysteine to methionine is impaired if
there is an insufficient vitamin B12 supply; consequently, plasma
homocysteine concentration increases.[42] However, the homo-
cysteine concentration is influenced not only by vitamin B12
but also by folate, vitamin B6, and riboflavin (vitamin B2).
Insufficient supply of these vitamins can also lead to increased
homocysteine concentrations.[43] The latter may also occur as a
consequence of renal insufficiency, dehydration, and cystathion-
ine β-synthase deficiency as well as certain polymorphisms of the
methylenetetrahydrofolate reductase.[44] Therefore, the homo-
cysteine concentration is a sensitive but non-specific functional
marker of vitamin B12 status.[26] Accordingly, the homocysteine
concentration is suitable to assess the vitamin B12 status only in
combination with a vitamin B12 status parameter (serumholo-TC
or vitamin B12).[30] In general, a plasma homocysteine concentra-
tion of <12 µmol L−1 in adults is considered to be adequate.[45]
4. Bioavailability of Vitamin B12
The bioavailability of vitamin B12 mainly depends on the intake
level and decreases with an increasing dose.[46] The approximate
absorption rates for the intake of 1, 5, 10, and 20 µg are 50%, 20%,
10%, and only 5%, respectively.[47] In addition to the dosage, the
food matrix determines the absorption rate of vitamin B12.[17,47]
The absorption rate when consuming lamb with a vitamin B12
content of 2.6 µg per 100 g is 56–89%, and for fish (rainbow
trout with 4.9 µg per 100 g), the absorption rate is 42%. For
cow’s milk (0.4 µg per 100 g), a bioavailability of 65% has been
determined.[17] The absorption rate for eggs with an average vita-
min B12 content of 1.3 µg per 100 g is <9%.[17] Based on a meta-
regression analysis of eight bioavailability studies, absorption
rates of 37% and 29%were determined for an intake of 1.2–3.1 µg
vitamin B12, respectively, per meal complying with the usual di-
etary habits.[46] At an average vitamin B12 intake of 1.2 µg per
meal, the bioavailability is 37%,[46] which means that for a mixed
diet, which contains vitamin B12 also from foods with lower
bioavailability,[17] an availability of 35–40% may be assumed.
Vitamin B12 produced by colon bacteria in the human gut can-
not be absorbed due to missing receptors.[48]
5. Derivation of the Reference Values for the Intake
of Vitamin B12
5.1. Adults
5.1.1. Adults under 65 Years of Age
As criteria to derive the reference value of vitamin B12 intake in
adults, the serum concentrations of holo-TC ( 40 pmol L−1)
and of the functional parameter MMA in the desirable range
of <270 nmol L−1 are considered as the most important ones.
These criteria are based on the results of two studies, in which
the adequate vitamin B12 intake was determined using the
serum concentrations of total vitamin B12 and holo-TC as well as
the functional parameters MMA and homocysteine.[13,14] In the
cross-sectional study by Bor et al.[13] with subjects aged 18 to 50
years, an average serum holo-TC concentration of 65 pmol L−1
was reached with a daily median intake of 4.2 µg vitamin B12;
higher intake levels were not associated with higher holo-TC
concentrations. The serum concentration of vitamin B12 reached
an average of 325 pmol L−1. For the functional parameters MMA
and homocysteine, average concentrations of 210 nmol L−1
and 8 µmol L−1, respectively, were measured,[13] which indicate
adequate vitamin B12 supply.[28] The intake of more than 7 µg d−1
during this study did not result in a further increase in the
plasma vitamin B12 concentration. With an intake of 7 µg d−1,
the lowest serum concentrations of MMA and homocysteine
were approximately 190 nmol L−1 and approximately 7 µmol
L−1, respectively.[13]
More data on the dose-response relationship between the vi-
tamin B12 intake and the serum concentrations of MMA, ho-
mocysteine and vitamin B12 are available from a randomized
controlled intervention study including 231 subjects.[14] In this
study, the lowest MMA and homocysteine concentrations were
190 nmol L−1 and 8.2 µmol L−1, respectively, with an intake of
approximately 7 µg vitamin B12 d−1 (4 µg d−1 from foods plus
3.4 µg d−1 from a supplement). This dietary intake resulted in a
serum concentration of vitamin B12 of approximately 330 pmol
L−1. At a dietary intake of 4.0 µg vitamin B12, the serum con-
centrations of vitamin B12, MMA, and homocysteine were ap-
proximately 300 pmol L−1, 220 nmol L−1, and 8.3 µmol L−1,
respectively.[14]
Based on the data from the studies by Bor et al.[13] and Pentieva
et al.[14] as well as on the target concentrations for total serum
vitamin B12 (>221 pmol L−1), holo-TC (40 pmol L−1), MMA
(<270 nmol L−1), and homocysteine (<12 µmol L−1), the esti-
mated value for the vitamin B12 intake is 4.0 µg d−1 for men and
women within the age range of 19 and 65 years (Table 1).
5.1.2. Adults above 65 Years of Age
In a study by Bor et al.[15] on osteoporotic women and women at
risk of osteoporosis at the age of 41 to 75 years, a median holo-TC
serum saturation of 119 pmol L−1 was achieved at a daily intake
of 6 µg vitamin B12. At this dose, the median serum concentra-
tion of vitamin B12 was 380 pmol L−1. Median concentrations of
MMA and homocysteine were 120 nmol L−1 and 9.75 µmol L−1,
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Table 1. Estimated values for adequate intake of vitamin B12.
Group Vitamin B12
Infants µg d−1
0 to under 4 months 0.5
4 to under 12 months 1.4
Children and adolescents
1 to under 4 years 1.5
4 to under 7 years 2.0
7 to under 10 years 2.5
10 to under 13 years 3.5
13 to under 15 years 4.0
15 to under 19 years 4.0
Adults
19 to under 25 years 4.0
25 to under 51 years 4.0
51 to under 65 years 4.0
65 years and older 4.0
Pregnant women 4.5
Lactating women 5.5
respectively,[15] which indicate adequate vitamin B12 supply.[28]
However, 36%of the subjects had a gastric pHof3 or other indi-
cations of gastric dysfunction.[15] Those dysfunctions could cause
an inhibition of gastric acid and pepsinogen secretion, which re-
sults in a reduced release of free vitamin B12 from food proteins,
hence decreasing intestinal absorption of the cobalamin protein
complexes from food. Furthermore, the reduced acid secretion
leads to an alkalinization of the small intestine, which may re-
sult in bacterial overgrowth and thus to a further decrease of the
bioavailability of vitamin B12.
A cross-sectional study inGermanwomen at the age of 60 to 70
years (n= 178) showed that at an average intake of 5 µg d−1, 43%
of the women had a serum cobalamin concentration of less than
258 pmol L−1.[49] This concentration was defined in the study as
a limit for sufficient supply. To derive the reference values for vi-
tamin B12 intake, a concentration range of 148 to 221 pmol L−1
was defined as suboptimal, while a concentration of >221 pmol
L−1 indicated sufficient supply. However, only 10% of the sub-
jects in the study by Wolters et al.[49] had an MMA concentration
>271 nmol L−1. An MMA concentration of <270 nmol L−1 was
considered the target concentration for a sufficient supply.
Currently, the available data are not sufficient to derive refer-
ence values for adults above 65 years of age for vitamin B12 intake
that are different from those for younger adults. Thus, the esti-
mated value for vitamin B12 intake for adults above 65 years of
age does not differ from that for younger adults independent of
gender and is set to 4.0 µg d−1 (Table 1).
5.2. Children and Adolescents
No data are available regarding the vitamin B12 requirement for
children and adolescents. Therefore, the reference values for chil-
dren and adolescents are based on the values compiled for adults
and take into account the differences in body weight, an allomet-
ric exponent and the growth factors to consider the requirements
for growth (Table 2). Growth factors at the different age groups
were calculated as the proportional increase in protein require-
ment for growth relative to themaintenance requirement accord-
ing to the WHO.[1,50] When using the age groups and reference
body weights the D-A-CH reference values are based upon,[1]
the resulting estimated values for vitamin B12 intake range from
1.5 µg d−1 (for 1 to under 4 year olds) to 4.0 µg d−1 (for 15 to under
19 year olds) (Table 2).
5.3. Infants
The reference values for the intake of vitamin B12 for infants aged
0 to under 4 months were derived based on the vitamin B12 con-
tent of breast milk, which is considered to be the optimal diet for
infants.[51,52] The cobalamin content of breastmilk varies depend-
ing on the duration of breastfeeding[53] and maternal vitamin B12
supply.[54] It declines continuously during the lactation period.[55]
In a Danish study, in which the majority of the women had taken
a multivitamin supplement (1.0–4.5 µg vitamin B12 d−1), the vi-
tamin B12 content of the breast milk was 0.1 µg per 100 mL
two weeks postpartum and 0.04 µg per 100 mL four months
postpartum[53] with a median vitamin B12 content in breast milk
in the first four months of 0.07 µg per 100 mL.[53] Assuming that
the median vitamin B12 content of breast milk during the first
four months is 0.07 µg per 100 mL, an exclusively breastfed in-
fant receives 0.53 µg d−1 vitamin B12 from breast milk of moth-
ers with adequate vitamin B12 supply at an average breast milk
intake of 750 mL d−1.[56] Therefore, the estimated value for the
adequate intake of vitamin B12 for breastfed infants aged 0 to un-
der 4 months is set at 0.5 µg d−1 (Table 3).
The consumption of breastmilk declines with the introduction
of solid foods. Since no data are available from Germany with re-
gard to vitamin B12 intake via solid foods, the estimated value for
infants aged 4 to under 12 months is based on the values com-
piled for adults and considers differences in the body weight, an
allometric exponent and a growth factor to consider the require-
ments for growth. An estimated value of 1.4 µg d−1 vitamin B12
for infants aged 4 to under 12 months was derived (Table 2).
5.4. Pregnancy
The requirement of pregnant women is slightly increased tomeet
the vitamin B12 requirement of the fetus. It was estimated that the
fetus accumulates 0.1 to 0.2 µg vitamin B12 per day.[57] Consider-
ing an absorption rate of 35–40%, the estimated value for vita-
min B12 intake for pregnant women is therefore set to 4.5 µg d−1
(Table 1).
5.5. Lactation
In comparison to the vitamin B12 requirement of non-lactating
women, the requirement of lactating women is increased due to
vitamin B12 secretion from breast milk. Approximately 0.5 µg d−1
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Table 2. Estimated values for vitamin B12 intake for infants (4 to under 12 months), children and adolescents considering differences in body weight,
allometric exponent, and growth factors.
Age [years] Gender Reference body
weight [kg]a)[1]
Growth factorb)[1] Vitamin B12 intake considering reference
body weight, allometric exponent and
growths factorc) [µg d–1]
Estimated value for vitamin B12
intake (rounded) [µg d−1]
4 to under 12 months m 8.6 0.70 1.40 1.4
f 7.9 0.70 1.49
1 to under 4 m 13.9 0.25 1.47 1.5
f 13.2 0.25 1.60
4 to under 7 m 20.2 0.06 1.66 2.0
f 20.1 0.06 1.87
7 to under 10 m 29.3 0.13 2.34 2.5
f 28.7 0.13 2.60
10 to under 13 m 41.0 0.13 3.01 3.5
f 42.1 0.11 3.41
13 to under 15 m 55.5 0.10 3.66 4.0
f 54.0 0.07 3.95
15 to under 19 m 69.2 0.07 4.20 4.0
f 59.5 0.02 4.07
a)The reference values for body weight correspond to the median body weight determined in the German Health Interview and Examination Survey for Children and Adolescents
in Germany (KiGGS; 2003–2006).[126] In each case, the values reflect the midpoint of the respective age range; b)Growth factors at different ages were calculated as the
proportional increase in protein requirement for growth relative to the maintenance requirement according to WHO[1,50]; c)Calculated from: estimated valueadults x (reference
body weightinfants/children/adolescents/reference body weightadults)0.75 x (1 + growth factor); Estimated valueadults: 4.0 µg d−1 (Table 1). Reference body weightadults (age group 25
to under 51 years): men 70.7 kg, women 60.0 kg.[1]; Example: Estimated valueGirls, 1 to under 4 years = 4.0 µg d−1 × (13.2 kg per 60.0 kg)0,75 × (1 + 0.25) = 1.60.
Table 3. Calculation of the estimated value for vitamin B12 for breastfed infants aged 0 to under 4 months.
Age [month] Vitamin B12 content of breast
milka) [µg per 100 mL]
Breast milk intakeb) [mL d−1] Vitamin B12 intake given a breast
milk intake of 750 mL d−1 [mg d−1]
Estimated value for vitamin B12
intake (rounded) [mg d−1]
0 to under 4 months 0.07 750 0.53 0.5
a)[53]; b)[56].
vitamin B12 is secreted with breast milk (see 5.3 Infants). There-
fore, considering an absorption rate of 35–40%, lactating women
require an additional 1.5 µg d−1. Thus, the estimated value for
vitamin B12 intake during lactation is 5.5 µg d−1 (Table 1).
6. Preventive Aspects
In the following paragraphs, currently available data on vita-
min B12 are outlined in association with some health-related as-
pects. Dietary reference values are aimed at healthy individuals;
thus, the requirements of patients are not addressed.
6.1. Vitamin B12 and Cardiovascular Diseases
Sincemetabolic vitamin B12 deficiency impairs the remethylation
of homocysteine to methionine, serum homocysteine concentra-
tion increases.[42] It is well known that homocysteine is an in-
dependent risk factor for ischaemic heart disease and ischaemic
stroke.[58–60] By increasing the homocysteine concentration by
5 µmol L−1, the risk of coronary events increases by 18%.[60] With
an increase of 3 µmol L−1, the risk of stroke increases by 19%.[59]
However, it is not clear, whether this observation reflects a causal
relationship.[61] Nevertheless, genetic association studies,[62–64] in
vitro studies and animal studies indicate a causal link.[45,65] In
contrast, the results from clinical intervention studies with vi-
tamin B12, vitamin B6 and folate are contradictory. On the one
hand, supplementation with B vitamins has the potential to re-
duce the relative risk of stroke by approximately 10%,[66,67] but vi-
tamin B12 alone does not seem to exert a preventive effect.[67] Ad-
ditionally, vitamin B12 supplementation was not associated with a
reduced risk of coronary events and cardiovascular diseases.[66,68]
6.2. Vitamin B12 and Cancer
Vitamin B12 is essential for DNA methylation, genome integrity,
and chromosomal stability, which suggests a preventive effect of
vitamin B12 regarding the development of cancer.[69] For breast
cancer, a meta-analysis of 18 observational studies showed an in-
verse association with the risk of disease and vitamin B12 intake
but not for serum vitamin B12 concentration.[70] Furthermore, no
association was observed between dietary vitamin B12 intake[71] or
vitamin B12 status[72] and the risk of endometrial cancer and col-
orectal carcinoma.[73–77] Another meta-analysis investigated the
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association between vitamin B12 serum concentration and the
risk of renal cell cancer using data from seven cohorts. Compared
with the group with the lowest intake, subjects with the highest
intake had a relative renal cell cancer risk of 0.72 (95% CI =
0.52–1.00).[78]
On the other hand, it is discussed that increased serum vita-
min B12 concentration is associated with a higher risk of can-
cer. For example, in a meta-analysis of observational studies,
there was a positive association between vitamin B12 serum con-
centration and the risk of prostate cancer.[79] In a cohort study,
an increased serum vitamin B12 concentration (>600 pmol L−1)
was associated with an elevated total risk of cancer incidence.
The risk was highest within the first year of follow-up.[80] How-
ever, this association might be due to the increased intake of
animal-based foods, which is associated with high vitamin B12
intake (“spurious correlation”). Another cause for this associa-
tion may be cancer types that are already present but not yet di-
agnosed, as some cancer types are associated with higher serum
vitamin B12 concentrations.[81]
6.3. Vitamin B12, Miscarriages, and Neural Tube Defects
In observational studies, an insufficient supply of vitamin B12
during pregnancy is associated with an increased risk of
miscarriage.[82,83] Furthermore, maternal vitamin B12 status is
associated with the occurrence of neural tube defects in the
child.[84,85] However, it remains unclear whether this observation
reflects a causal relationship.[86]
6.4. Vitamin B12 and Bone-Related Diseases
Vitamin B12 deficiency and hyperhomocysteinaemia are linked
with the stimulation of osteoclast activity and accelerated degra-
dation of the bonematrix.[87–90] The data from observational stud-
ies on the association between vitamin B12 status or vitamin B12
intake and bone mineral density, the risk of fracture or bone
turnover markers are inconsistent.[88] In a meta-analysis of four
prospective studies, for each increase of total serum vitamin B12
concentration by 50 pmol L−1, a 4% reduced fracture risk was
calculated (95% CI = 0.92–1.00).[91] A meta-analysis of four
randomized controlled intervention studies indicates that the ef-
fect of vitamin B12 on the risk of fracture depends on the basal
homocysteine concentration. A protective effect of vitamin B12
supplementation may be expected only at homocysteine concen-
trations >15 µmol L−1 (75% risk reduction; 95% CI = 0.12–
0.53). There is no evidence that vitamin B12 supplementation in
excess of the individual requirement for subjects with adequate
supply of folate and vitamin B12 at homocysteine concentrations
<15 µmol L−1 results in a further fracture risk reduction.[92]
6.5. Vitamin B12, Neurodegenerative Diseases, and Cognitive
Impairment
There is also a discussion about the question of whether func-
tional vitamin B12 deficiency, which is characterized by decreased
concentrations of holo-TC and increased concentrations ofMMA
and/or homocysteine, is associated with an increased risk of neu-
rodegenerative diseases and cognitive impairment.[93,94] Several
epidemiological studies showed a positive correlation regarding
MMA concentrations and an inverse association regarding holo-
TC concentrations with the development or progression of de-
mentia, while there is only a low or no association between total
vitamin B12 concentrations and disease risk.[72,74,75,93,94] In older
people, vitamin B12 deficiency is also associated with cerebral
atrophy.[95,96] Vitamin B12 supplementation (0.5 mg d−1) in com-
bination with folate (0.8 mg d−1) and vitamin B6 (20 mg d−1)
in older people could slow cerebral atrophy over two years.
This effect is, however, dependent on baseline homocysteine
concentration.[97]
The concentrations of holo-TC and MMA have proved to be
good predictors of cognitive performance, while total vitamin B12
concentration has not been shown to be a good predictor, as
indicated by a longitudinal cohort study including 1648 senior
women and men (65 years) over a period of 10 years. An in-
crease of the holo-TC concentration from 50 to 100 pmol L−1 is
associated with a 30% lower reduction of cognitive performance;
the increase in MMA and homocysteine concentrations from
0.25 to 0.5 µmol L−1 and from 10 to 20 µmol L−1, respectively,
is associated with an impairment of cognitive performance by
>50%.[98]
The data from intervention studies on the influence of vita-
min B12 supplementation on cognitive performance are contra-
dictory; the effects seem to depend on the basal homocysteine
concentration and duration of the intervention. A systematic re-
view of 25 randomized controlled studies and cohort studies con-
cluded that there is insufficient evidence regarding an association
between vitamin B12 intake or vitamin B12 status, respectively,
and cognitive performance.[94] Another systematic review of ten
observational studies including subjects over 50 years had shown
similar results.[99]
7. Discussion and Conclusion
7.1. Vitamin B12 Reference Values—What has Changed?
The reference values for vitamin B12 intake from international
expert panels vary considerably.[57,100–102] This variance of recom-
mendations results from the fact that the scientific basis allows
a certain variation (see Table 4). Therefore, they have been the
subject of intense controversy. Since the publication of the first
D-A-CH reference values for the intake of vitamin B12, several
vitamin B12 biomarker studies have questioned whether the cur-
rent reference value of 3.0 µg vitamin B12 d−1 is adequate for op-
timal vitamin B12 status in healthy adults.[13–15] From this back-
ground, D-A-CH nutrition societies have reviewed and evaluated
vitamin B12-related biomarker studies and revised the reference
values for vitamin B12 in 2018.
Developing new reference values for vitamin B12 intake re-
quires the definition of the best target biomarkers for a supply,
corresponding to adequacy of metabolic functions. For adults,
the reference value for vitamin B12 intake is based on biomark-
ers of vitamin B12 status, notably adequate serum concentra-
tions of holo-TC and MMA. As a result, the revised vitamin B12
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reference value for adults was changed from a recommended in-
take value of 3 µg d−1 up to an estimated value of 4 µg d−1, which
is in line with the reference value of vitamin B12 of the European
Food Safety Authority (EFSA).[102]
7.2. Vitamin B12 Reference Values—Practical Aspects
According to the analysis of the data from the National Nutrition
Survey II (NVS II, 2005–2006), the median vitamin B12 intake in
Germany in women andmen between the ages of 15 and 80 years
is 3.8 and 5.3 µg d−1, respectively.[103,104]
The intake of foods naturally rich in cobalamin as part of a
mixed diet can ensure sufficient vitamin B12 supply. To achieve
sufficient vitamin B12 intake, a regular intake of animal-based
food such as milk and dairy products, fish, poultry and lean meat
is recommended. It should be noted that during food process-
ing, e.g., cooking or pasteurization, a vitamin B12 loss up to 50%
might occur.[105]
People adopting a vegan diet that excludes animal foods should
be encouraged to take a dietary vitamin B12 supplement and
should have their vitamin B12 status regularly checked by a
physician.[106] Spirulina and other cyanobacteria, which are ad-
vertised as natural vitamin B12 sources for vegans, do not con-
tain cobalamins that are bioavailable for humans. In addition, the
cobalamin analogues that they contain can even inhibit intestinal
uptake of vitamin B12 and might suppress the formation of bio-
logically active vitamin B12 coenzymes.[107,108] Therefore, they are
unsuitable to cover the requirements of vegans.
Partly, vitamin B12 deficiency represents a health issue for ovo-
lacto vegetarians.[105,109,110] Thus, it is recommended that vegetar-
ians should have their vitamin B12 status checked regularly by a
physician, too, and should take dietary supplements to achieve
sufficient vitamin B12 supply if necessary.[105,111–113] In particular,
vegetarians with increased nutrient requirements, for example,
due to pregnancy or lactation, should pay attention to sufficient
vitamin B12 intake.
In older people, the risk of vitamin B12 deficiency is in-
creased, mainly due to impaired absorption because of medi-
cation (e.g., proton pump inhibitors, H2 blockers) or diseases
(e.g., atrophic gastritis) and less due to insufficient dietary in-
take of vitamin B12.[114–117] In the case of atrophic gastritis with
hypochlorhydria and related malabsorption of dietary protein-
bound vitamin B12,[118,119] supplementation of vitamin B12 is rec-
ommended to ensure adequate vitamin B12 status.[114,116,120] In
contrast to vitamin B12 from natural foods, the absorption of crys-
talline vitamin B12 from preparations is not impaired in atrophic
gastritis type B-related hypochlorhydria.[116,120] However, inves-
tigations show that the use of dietary supplements or fortified
foods reduces the prevalence of vitamin B12 deficiency in older
people,[96,121–123] but the risk of insufficient supply in general per-
sists because of the dosage, which is often too low.[124,125] Thus,
a regular observation of the vitamin B12 status is also recom-
mended for older people. For the assessment of the vitamin B12
status, a relevant functional parameter such as MMA should be
combined with a status marker such as serum vitamin B12 or
holo-TC.
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